Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide vs Chemotherapy in Neoadjuvant HR+/HER2- Breast Cancer
NCT05253066Phase 3Unknown
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Feb 2022
- Primary completion
- Jul 2022
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of tucidinostat in Breast cancer (hormone receptor-positive/human epidermal growth factor receptor 2-negative) (2 arms), sponsored by Shengjing Hospital of China Medical University. Primary endpoint: Objective Response Rate up to 48 months. Status: unknown.
02
Drugs
tucidinostat
03
Conditions
Breast cancer (hormone receptor-positive/human epidermal growth factor receptor 2-negative)
Beyond the preview
Go deeper on NCT05253066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05253066.